Skip to main content
. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5

Fig. 1. Flow chart depicting treatment, response, and outcome of the study population.

Fig. 1

Allo-HSCT allogeneic hematopoietic stem cell transplantation, BM bone marrow, CR complete remission, CRi complete remission with incomplete hematologic recovery, CTX chemotherapy, DRM disease-related mortality, d day, fav favorable, FU follow-up, HD-AraC high-dose cytarabine, ID-AraC intermediate dose cytarabin, MLFS morphologic leukemia-free state, NRM non-relapse mortality, pat patient, PD progressive disease, PS performance status, rel related, SD stable disease, Tx transplant.